Valion Bio Total Revenue

Valion Bio (VBIO) currently reports a total revenue of $-160K as of June 2026. That compares with $460K in the prior-year period — down 133.8% year over year. That is below the sector sector average of $22T. Use the charts on this page to explore Valion Bio's total revenue history and peer comparisons.

Valion Bio's total revenue decreased from $460K to $-160K — a 133.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Valion Bio's total revenue of $-160K is lower than the its sector sector average of $22T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Valion Bio reported $-160K in total revenue as of June 2026. That compares with $460K in the prior-year period — down 133.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $-160K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $22T. From there, open related valuation or income-statement pages for Valion Bio, and consider following VBIO for alerts when major investors trade the stock.